• New treatment options against Carbapenem Resistant Acinetobacter Baumanii isolates
  • Zahra Mottaghiyan,1 Davoud Esmaeili,2,*
    1. Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran
    2. Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran


  • Introduction: Acinetobacter baumanii is a gram negative and opportunistic nosocomial pathogen that cause nosocomial infection such as Bacteremia, Ventilator Associated Pneumonia Surgical Site Infections, Secondary Meningitis and Urinary Tract Infections. Because of its ability to resist again almost antimicrobial agents including carbapenems, so the World Health Organization (WHO) identified this pathogen as a critical bacterium. Frequency of CRAB isolates have been reported increasingly so the problem of treating Acinetobacter baumannii infections has became a challenge. The emergence of CRAB isolates left several active antimicrobials including colistin, tigecycline, and sulbactam as β-lactamase inhibitor, but reported resistance to thess drugs. Colistin is consistently used as rescue therapy, but monotherapy with COL often leads to suboptimal clinical outcomes, which are attributed to uncertain dosing parameters as well as nephrotoxicity. The present study aimed to explore new treatment options against Carbapenem Resistant Acinetobacter Baumanii isolates
  • Methods: In this study various databases used to select articles in both Persian and English languages. Targeted databases were Google Scholar, PubMed, Scopus, Web of Science. The applied keywords included Carbapenem resistant Acinetobacter baumannii, CRAB isolates and treatment
  • Results: Studies showed that colistin combined with other antibiotics including sulbactam, meropenem and tigecyclin may be suitable combination for treatment carbapenem resistant A. baumannii infections. The results revealed that combined treatment of colistin with other antibiotics have shown superior clinical outcomes compared to colistin alone so to limit nephrotoxicity side effect and reduce resistance to this drug, combination therapy is suggested
  • Conclusion: In Conclusion, some of these studies were conducted in invitro conditions, so for better conclusions and clinical use of these drugs, need further trials and more investigations in invivo conditions to confirm this findings
  • Keywords: Carbapenem resistant, Acinetobacter baumannii, treatment